Leiner’s Return To U.S. OTC Market Complicated By FDA Warning, DOJ Inquiry
This article was originally published in The Tan Sheet
Executive Summary
FDA's investigation into manufacturing and quality control issues at Leiner Health Products' South Carolina facility revealed a culture of mismanagement that created a pattern of undetected production errors and overlooked discrepancies regarding product development, according to the agency